title: Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia in an HIV-infected patient with von Recklinghausen disease.
abstract: The antiretroviral agent tenofovir can cause hypophosphatemic osteomalacia due to renal phosphate wasting. The potential role for Fibroblast Growth Factor 23 (FGF23), a phosphaturic hormone is unknown. We evaluated FGF23 plasma concentrations in an HIV-positive patient with neurofibromatosis in whom hypophosphatemia developed during tenofovir therapy. This patient presented with diffuse pain, hypophosphatemia and tubular dysfunction with inadequate phosphate reabsorption. The full recovery after tenofovir discontinuation indicates that the hypophosphatemia was related to tenofovir and not to von Recklinghausen disease. Our data argue against a role for FGF23 in tenofovir-induced hypophosphatemia nor in the regulation of hypophosphatemia in this situation.
authors.affiliation: EA4222, University of Paris 13, rue Marcel-Cachan, Bobigny, France. nathalie.saidenberg@avc.ap-hop-paris.fr
authors.forename: Nathalie
authors.initials: N
authors.lastname: Saidenberg-Kermanac'h
authors.forename: Leila
authors.initials: L
authors.lastname: Souabni
authors.forename: Virginie
authors.initials: V
authors.lastname: Prendki
authors.forename: Dominique
authors.initials: D
authors.lastname: Prie
authors.forename: Marie-Christophe
authors.initials: MC
authors.lastname: Boissier
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000378:metabolism*; D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D057915:Drug Substitution; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D008297:Male; D009456:Neurofibromatosis 1 / Q000188:drug therapy / Q000378:metabolism*; D063065:Organophosphonates / Q000009:adverse effects*; D010018:Osteomalacia / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism; D010710:Phosphates / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D000068698:Tenofovir; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; C000717427:FGF23 protein, human; D063065:Organophosphonates; D010710:Phosphates; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D000068698:Tenofovir; D000225:Adenine